⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

Official Title: A Phase II, Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU-0059436 Given Orally Twice Daily in Patients With Advanced BRCA1- or BRCA2-associated Breast Cancer.

Study ID: NCT00494234

Interventions

Olaparib

Study Description

Brief Summary: The purpose of the study is to see if the drug KU-0059436 (olaparib) is effective and well tolerated in treating participants with measurable breast cancer gene (BRCA)1- or BRCA2-positive advanced breast cancer and for whom no curative therapeutic option exists.

Detailed Description: This is a Phase II, open-label, non-comparative, international, multicenter study to assess the efficacy and safety of olaparib when given orally twice daily (bd) in participants with advanced BRCA1- or BRCA2- associated breast cancer. Two sequential participant cohorts will receive continuous oral olaparib in 28-day cycles. The first cohort will receive 400 mg bd and the second cohort will receive 100 mg bd.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Research Site, West Hollywood, California, United States

Research Site, Boston, Massachusetts, United States

Research Site, Melbourne, , Australia

Research Site, Randwick, , Australia

Research Site, Duarte, CA, Canada

Research Site, Kiel, , Germany

Research Site, Köln, , Germany

Research Site, München, , Germany

Research Site, Tel-Aviv, , Israel

Research Site, Hospitalet deLlobregat, , Spain

Research Site, Madrid, , Spain

Research Site, Lund, , Sweden

Research Site, Cambridge, , United Kingdom

Research Site, Edinburgh, , United Kingdom

Research Site, Fulham, , United Kingdom

Research Site, London, , United Kingdom

Research Site, Manchester, , United Kingdom

Contact Details

Name: James Carmichael, BSc, MBChB, MD, FRCP

Affiliation: KuDOS Pharmaceuticals Limited

Role: STUDY_DIRECTOR

Name: Andrew Tutt, PhD MRCP FRCR

Affiliation: Guy's and St Thomas's NHS Foundation Trust, London, UK

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: